A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers.  BRCA2, a crucial player in the body& | Cancer ...